AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained
Tip Ranks·- Bank of America Securities analyst Sachin Jain maintained a buy rating on AstraZeneca with a target price of 16,500 pence. - The rating is supported by strong oncology performance and pipeline catalysts that offset the setback of the Phase III trial failure of volrustomig. - Jefferies also maintained a buy rating on the stock with a target price of 175.00 pounds in a separate report.